galactosyl-(1-3)galactose has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cabezas-Cruz, A; Cabrera, CM; Contreras, M; de la Fuente, J; Fernández de Mera, IG; Ferreras-Colino, E; Gortázar, C; Urra, JM; Villar, M | 1 |
1 other study(ies) available for galactosyl-(1-3)galactose and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The antibody response to the glycan α-Gal correlates with COVID-19 disease symptoms.
Topics: Aged; Aged, 80 and over; Antibodies, Bacterial; Antibodies, Viral; COVID-19; Disaccharides; Epitopes; Female; Humans; Immunity, Humoral; Immunoglobulin G; Male; Microbiota; Middle Aged; Severity of Illness Index; Spain | 2021 |